Researchers Uncovered a New Mechanism of Neurodegeneration

Technology Networks | November 22, 2019

Charcot-Marie-Tooth disease (CMT) is an inherited neurodegenerative condition that affects 1 in 2500 individuals. Currently, however, it is still lacking effective treatment options. New research has demonstrated that a class of cytoplasmic enzymes called tRNA synthetases can cause CMT by interfering with the gene transcription in the nucleus. This breakthrough is the result of an international academic collaboration, where scientists from the VIB-UAntwerp Center for Molecular Neurology and the Scripps Research Institute were the driving force. The study was published in the leading journal Nature Communications. Charcot-Marie-Tooth disease (CMT) is a condition that affects the peripheral nervous system. It leads to progressive muscle weakness and loss of sensation in the lower and - later on - upper limbs. It is the most commonly inheritable neuromuscular disorder and, at the moment, remains incurable. The first symptoms can appear both in early childhood or during adult life. Over 90 genes are implicated in the pathology so far and these are involved in a variety of processes. This complexity makes it a difficult condition to study and find a treatment for.

Spotlight

Industrial biotechnology has answers for many pressing questions of our world. The Austrian Centre of Industrial Biotechnology (acib) develops new solutions to make industrial processes more economic and ecological - using the hidden concepts of nature.


Other News
CELL AND GENE THERAPY

Clearmind Announces Notice of Proposed Stock Consolidation

Clearmind Medicine Inc. | September 26, 2022

Clearmind Medicine Inc. a biotech company focused on discovery and development of novel psychedelic-derived therapeutics to solve major undertreated health problems, announces that it will be consolidating all of the issued and outstanding common shares of the Company on the basis of one (1) post consolidation Common Share for each thirty (30) pre consolidation Common Shares. The Corporation's board of directors set September 30, 2022 as the effective date of the Consolidation. Trading of the Common Shares on a post-Consolidation basis on the Canadian Securities Exchange will commence on or about October 3, 2022. The Company's name and trading symbol will remain unchanged. The 39,592,344 Common Shares currently issued and outstanding will be reduced to approximately 1,319,744 Common Shares on a post-Consolidation basis. No fractional shares will be issued. Any fractional interest in Common Shares will be rounded up to the nearest whole Common Share. Letter of transmittals will be mailed to registered Shareholders and registered Shareholders will be required to deposit their share certificate(s), together with the duly completed letter of transmittal, with Computershare Investor Services Inc., the Company's registrar and transfer agent. Non-registered Shareholders holding Common Shares through an intermediary should be aware that the intermediary may have different procedures for processing the Consolidation than those that will be put in place by the Company for registered Shareholders. If Shareholders hold their Common Shares through intermediaries and have questions in this regard, they are encouraged to contact their intermediaries. Outstanding stock options and share purchase warrants will also be adjusted by the Consolidation ratio and the respective exercise prices of outstanding options and share purchase warrants will be adjusted accordingly. About Clearmind Medicine Inc. Clearmind is a psychedelic pharmaceutical biotech company focused on the discovery and development of novel psychedelic-derived therapeutics to solve widespread and underserved health problems, including alcohol use disorder. Its primary objective is to research and develop psychedelic-based compounds and attempt to commercialize them as regulated medicines, foods or supplements. The Company’s intellectual portfolio currently consists of seven patent families. The Company intends to seek additional patents for its compounds whenever warranted and will remain opportunistic regarding the acquisition of additional intellectual property to build its portfolio.

Read More

CELL AND GENE THERAPY

Biotimize Announces the Opening of a Fundraising Round to Build the First Biological CDMO in Brazil

Biotimize | September 06, 2022

Biotimize, a functional growth-stage biotechnology as a service company with a mission to transform lives through biotechnology, today announced the opening of a $30 million Series A fundraising round. The investment will enable Biotimize to build the first biological CDMO in Brazil and to become the first end-to-end biological CDMO in South America. Brazilian universities, startups, and medium-large companies face enormous challenges in developing biological Active Pharmaceutical Ingredients. These difficulties are evidenced by the low number of biopharmaceutical products launched through 100% Brazilian research, a sub-optimal biological manufacturing capacity the low number of facilities with an active GMP certification, and the very high cost of importing biological products. Among many causes, this has occurred chiefly due to the absence of any Brazilian biological CDMOs, despite the existence of more than 500 worldwide. Recent efforts have sought to change the historically discouraging biopharmaceutical scenario in Brazil. The Brazilian government has legislated several industrial incentives and the Brazilian Health Regulatory Agency is also enforcing strict adherence to the ICH guidelines. “The impact of building the CDMO goes far beyond the financials. Biotimize will help build the foundation for a growing scientific community that currently has no structure for development or GMP production,” says Fernando Barbosa, CEO of Biotimize. A 32,000 square-foot parcel of land was donated to Biotimize by the City of Piracicaba, and Biotimize is negotiating partnerships with world renowned equipment suppliers, centers of API characterization and GMP training organizations. “The CDMO will have independent upstream suites for mammalian cell cultures focused on recombinant protein production, like monoclonal antibodies. This is especially important for a country with over 200 million inhabitants and a large potential market for biosimilars,” adds Fernando. About Biotimize Biotimize is a Biotechnology as a Service company led by entrepreneurs with solid experience in innovation, acquired in different companies and research centers around the world. With a mission to transform lives through biotechnology, Biotimize enables ideas, treatments, and dreams to become reality. Biotimize is on its way to being the first biological CDMO in Brazil.

Read More

INDUSTRIAL IMPACT

Beren Awarded Expedited Roadmap for Treatment of Homozygous Familial Hypercholesterolemia

Beren Therapeutics | November 18, 2022

Beren Therapeutics, P.B.C. a biotechnology company, announced that its novel lead asset, BRN-002, was awarded an Innovation Passport under the United Kingdom’s Innovative Licensing and Access Pathway for the reversal of atherosclerosis in patients with Homozygous Familial Hypercholesterolemia. The ILAP aims to accelerate the time to market for innovative medicines that address the needs of patients with life-threatening or seriously debilitating diseases. HoFH is a rare genetic disease where patients have high levels of LDL cholesterol typically beginning in childhood causing plaque to build up in the arteries. The disease is currently managed with LDL-apheresis beginning as early as the age of seven and other LDL-lowering therapies. Despite the current therapies and treatments, the average patient life expectancy is between 30 and 40 years. It is estimated that HoFH affects as many as 1 in 250,000 people in the UK. Untreated, HoFH results in premature heart disease including heart attacks and aortic valve disease beginning in the early teen years and sometimes even earlier, resulting in a large impact on quality of life. BRN-002 is being developed to reverse the underlying cause of atherosclerosis, plaque in the arteries. Currently, there are no approved therapies or treatments that reverse atherosclerosis. “The Innovation Passport provides Beren the opportunity to collaborate with MHRA and its partner agencies to develop a roadmap for development and regulatory milestones with the primary goal of achieving early patient access for the treatment of HoFH in the UK while ensuring patient safety and efficacy. The inter-agency collaboration model inherent to the ILAP program is ideal for developing novel therapies that can broadly impact patients and public health. Programs like ILAP align with Beren’s founding vision to develop novel therapies hand in hand with the relevant stakeholders and to make the right decisions at the right time to optimize for speed to approval, and access and distribution once approved. We are excited to begin work under ILAP, and look forward to collaborating with other regulators, payors and governments to expedite development and identify and remove access barriers.” Jason Camm, Beren CEO “HoFH patients desperately need novel treatments to halt and reverse this debilitating disease, and the acceleration of this clinical program will hopefully allow a new medicine to be available sooner,” said Jules Payne, CEO of HEART UK. “Significant unmet needs remain and with this advancement, we are hopeful for a new treatment option that can truly alter the course of the disease for the children and patients living with HoFH.” About ILAP and Innovation Passport The Innovation Passport is awarded by the UK’s Innovation Licensing and Access Pathway Steering Group, which consists of representatives from MHRA, NICE, the Scottish Medicines Consortium and the National Health Service England. The ILAP aims to accelerate the time to market and facilitate patient access to medicines through the development of a target development profile (TDP) that outlines a unique product-specific roadmap for regulatory and development milestones. Other benefits provided by ILAP include the potential for a 150-day accelerated assessment of a Marketing Authorization Application (MAA) and rolling review. The ILAP also provides opportunities for frequent interactions with the review staff at the MHRA and its partner agencies to discuss the drug’s development and regulatory plans, as well as reimbursement. About Beren Therapeutics, P.B.C. Beren Therapeutics, P.B.C. is currently in stealth.

Read More

INDUSTRIAL IMPACT

Agilent Attains ‘Angel’ Level Sponsorship with My Green Lab

Agilent Technologies | December 01, 2022

cevel sponsor of My Green Lab, a nonprofit organization dedicated to building a global culture of sustainability in science. ‘Angel’ level sponsorship provides Agilent access to even more strategic counsel from My Green Lab in support of its sustainability activities and expertise that can be shared with customers. Agilent is also the proud sponsor of the My Green Lab Certification program – considered the gold standard for laboratory sustainability best practices. As a good citizen and role model for customers, Agilent is working to ensure its on-site customer demonstration laboratories globally are Green Lab Certified and have already achieved highest level certification for Waldbronn, Germany, Cheadle, UK, and Santa Clara, US sites. “Sustainability and environmental, social, and governance standards are central to our mission to advance the quality of life, and our sponsorship of My Green Lab helps us to drive this forward. Being an ‘Angel’ level sponsor will further cultivate our knowledge of creating sustainable green labs, which we can share with our customers globally and support them on their sustainability journey.” Darlene Solomon, senior vice president, and chief technology officer at Agilent The Green Lab Certification from My Green Lab is recognized by the United Nations Race to Zero campaign as a key measure of progress for pharmaceutical and medical technology companies toward a zero-carbon future. It indicates that a lab has achieved strong sustainability practices in energy use, water consumption, recycling, and waste production. About Agilent Technologies Agilent Technologies Inc. is a global leader in the life sciences, diagnostics, and applied chemical markets, delivering insight and innovation that advance the quality of life. Agilent’s full range of solutions includes instruments, software, services, and expertise that provide trusted answers to our customers' most challenging questions. The company generated of $6.85 billion in fiscal 2022 and employs 18,000 worldwide.

Read More

Spotlight

Industrial biotechnology has answers for many pressing questions of our world. The Austrian Centre of Industrial Biotechnology (acib) develops new solutions to make industrial processes more economic and ecological - using the hidden concepts of nature.

Resources